Skip to content
Dr. Cameron Hudson, Senior Vice President OUS, Elios Vision, and Professor Keith Barton, co-founder of the IGSR.

Elios Vision announces collaboration with the International Glaucoma Surgical Registry

Elios Vision is proud to announce our collaboration and support for the International Glaucoma Surgical Registry (IGSR). The IGSR is an open-access tool which enables surgeons to upload and analyze their data and compare outcomes with other centres. The IGSR has been established for over five years and currently holds data for 7,000 procedures across 63 countries. In 2019, the IGSR became the official registry partner of the European Glaucoma Society (EGS).

“We are delighted to collaborate with and support the objectives of the International Glaucoma Surgical Registry. Capturing long-term, real-world evidence is of high importance especially when adopting and integrating new surgical treatments. We hope the collaboration will encourage other surgeons to utilize the platform for audit and data generation purposes”, said Dr. Cameron Hudson, Senior Vice President OUS, Elios Vision.

Professor Keith Barton, co-founder of the IGSR with Dr. Nathan Kerr, said, “We are grateful for the support of Elios Vision in furthering the objectives of the International Glaucoma Surgical Registry and look forward expanding the capabilities of the registry through their support.”

About Elios Vision Inc.
Elios Vision Inc. is a privately held medical device company focused on the commercialization of ELIOS, a novel MIGS technology used to treat glaucoma. ELIOS uses excimer laser energy to create microscopic openings (microchannels) in the trabecular meshwork (TM) to re-establish the natural flow of aqueous. ELIOS avoids the needs for implants as with some conventional MIGS and has demonstrated long-lasting IOP and medication reduction for patients for up to eight years post-operatively.1

Media & Investor Contact
Matt Coleman
matt@eliosvision.com


  1. Riesen M, Funk J, Töteberg-Harms M. Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study. Graefes Arch Clin Exp Ophthalmol. Published online January 16, 2022. doi:10.1007/s00417-021-05510-8.

Share This Story

Latest News

Video: Combined Phacoemulsification and ELIOS for Medication Reduction

Dr. Antonio Moreno-Valladares discusses a recent study of medication reduction outcomes for the ELIOS procedure combined with phacoemulsification.
Elios Vision logo

Elios Vision achieves three new pipeline milestones

Elios announced enrollment completion in their U.S. pivotal trial, the expansion of the U.S. pre-launch team, and continued commercial uptake in Europe.
The Ophthalmologist logo

The ELegance of ELIOS

Learn why Dusseldorf-based surgeon Karsten Klabe prefers the ELIOS procedure when treating patients for open-angle glaucoma.
×

Site for Healthcare Professionals Only

You are about to access Elios Vision’s online platform for healthcare professionals outside of the United States. This platform is intended to provide general product information for education and illustration purposes. It is not intended to provide information to the general public or medical advice.

As product information, availability, indication, and trade names may vary from country to country, the content of this site may not be fully in-line with the approved or cleared product information in the country you are accessing from. Unless stated otherwise for specific product or event pages, the content on this site is based on the regulatory and legal principles applicable to the United Kingdom.

By closing this popup, I confirm that:

  • I understand that this platform is directed to Healthcare Professionals only and that I am a licensed Healthcare Professional.
  • I have read and agree to Elios Vision’s terms and conditions and privacy policy.